Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201170
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ten-Blanco, Marc | - |
dc.contributor.author | Flores de los Heros, África | - |
dc.contributor.author | Cristino, Luigia | - |
dc.contributor.author | Pereda Pérez, Inmaculada | - |
dc.contributor.author | Berrendero, Fernando | - |
dc.date.accessioned | 2023-07-25T11:10:12Z | - |
dc.date.available | 2023-07-25T11:10:12Z | - |
dc.date.issued | 2023-04-02 | - |
dc.identifier.issn | 0091-3022 | - |
dc.identifier.uri | http://hdl.handle.net/2445/201170 | - |
dc.description.abstract | Orexins (also known as hypocretins) are neuropeptides located exclusively in hypothalamic neurons that have extensive projections throughout the central nervous system and bind two different G protein-coupled receptors (OX1R and OX2R). Since its discovery in 1998, the orexin system has gained the interest of the scientific community as a potential therapeutic target for the treatment of different pathological conditions. Considering previous basic science research, a dual orexin receptor antagonist, suvorexant, was the first orexin agent to be approved by the US Food and Drug Administration to treat insomnia. In this review, we discuss and update the main preclinical and human studies involving the orexin system with several psychiatric and neurodegenerative diseases. This system constitutes a nice example of how basic scientific research driven by curiosity can be the best route to the generation of new and powerful pharmacological treatments. | - |
dc.format.extent | 24 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.yfrne.2023.101066 | - |
dc.relation.ispartof | Frontiers in Neuroendocrinology, 2023, vol. 69, num. 101066 | - |
dc.relation.uri | https://doi.org/10.1016/j.yfrne.2023.101066 | - |
dc.rights | cc by (c) Ten-Blanco, Marc et al., 2023 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Malalties neurodegeneratives | - |
dc.subject.classification | Neuropèptids | - |
dc.subject.classification | Animals | - |
dc.subject.classification | Proteïnes G | - |
dc.subject.other | Neurodegenerative Diseases | - |
dc.subject.other | Neuropeptides | - |
dc.subject.other | Animals | - |
dc.subject.other | G Proteins | - |
dc.title | Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: from animal to clinical studies | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 733413 | - |
dc.date.updated | 2023-07-25T11:10:12Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37015302 | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
733413.pdf | 11.17 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License